0001564590-21-045342 | 6-K | XBRL Viewer

Print Document View Excel Document

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2021
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Entity Registrant Name	LEGEND BIOTECH CORPORATION
Entity Central Index Key	0001801198
Current Fiscal Year End Date	--12-31

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Statement Of Profit Or Loss And Other Comprehensive Income [Abstract]
REVENUE	$ 33,915	$ 23,146
Other income and gains	2,390	3,796
Research and development expenses	(154,529)	(101,570)
Administrative expenses	(17,991)	(7,938)
Selling and distribution expenses	(30,199)	(16,102)
Other expenses	(4,378)	(82)
Fair value loss of warrant liability	(1,600)
Fair value loss of convertible redeemable preferred shares		(79,984)
Finance costs	(90)	(4,079)
LOSS BEFORE TAX	(172,482)	(182,813)
Income tax credit/(expense)	(1)	3,709
LOSS FOR THE PERIOD	(172,483)	(179,104)
Attributable to:
Equity holders of the parent	$ (172,483)	$ (179,104)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT
Ordinary shares—basic and diluted	$ (0.63)	$ (0.86)
Exchange differences:
Exchange differences on translation of foreign operations	$ 3,305	$ (213)
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	3,305	(213)
OTHER COMPREHENSIVE (LOSS)/INCOME FOR THE PERIOD, NET OF TAX	3,305	(213)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	(169,178)	(179,317)
Attributable to:
Equity holders of the parent	$ (169,178)	$ (179,317)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION AND UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)	Jun. 30, 2021	Dec. 31, 2020
NON-CURRENT ASSETS
Property, plant and equipment	$ 135,216,000	$ 113,091,000
Advance payments for property, plant and equipment	2,197,000	224,000
Right-of-use assets	7,312,000	8,009,000
Other non-current assets	4,885,000	3,973,000
Intangible assets	4,681,000	2,852,000
Total non-current assets	154,291,000	128,149,000
CURRENT ASSETS
Inventories	1,700,000	1,800,000
Trade receivables	15,000,000	74,978,000
Prepayments, other receivables and other assets	11,170,000	10,007,000
Financial investment measured at amortized cost	29,849,000
Pledged short-term deposits	256,000	384,000
Time deposits	174,644,000	50,000,000
Cash and cash equivalents	488,215,000	455,689,000
Total current assets	720,834,000	592,858,000
Total assets	875,125,000	721,007,000
CURRENT LIABILITIES
Trade and notes payables	11,001,000	5,238,000
Other payables and accruals	109,183,000	99,168,000
Lease liabilities	1,178,000	1,464,000
Government grants	300,000	283,000
Warrant liability	83,300,000
Contract liabilities	56,139,000	55,014,000
Total current liabilities	261,101,000	161,167,000
NON-CURRENT LIABILITIES
Contract liabilities	252,628,000	275,071,000
Lease liabilities	1,621,000	1,909,000
Other non-current liabilities	554,000	554,000
Interest-bearing loans and borrowings	17,310,000
Government grants	1,992,000	2,051,000
Total non-current liabilities	274,105,000	279,585,000
Total liabilities	535,206,000	440,752,000
EQUITY
Share capital	29,000	27,000
Reserve	339,890,000	280,228,000
Total ordinary shareholders’ equity	339,919,000	280,255,000
Total equity	339,919,000	280,255,000
Total liabilities and equity	$ 875,125,000	$ 721,007,000

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Share Capital	Share Premium	Share-based Compensation Reserves	Foreign Currency Translation Reserve	Accumulated Losses
Beginning balance at Dec. 31, 2019	$ (122,869)	$ 20	$ 3,908	$ 1,976	$ (1,491)	$ (127,282)
Loss for the period	(179,104)					(179,104)
Other comprehensive income:
Exchange differences on translation of foreign operations	(213)				(213)
Total comprehensive income/(loss) for the period	(179,317)				(213)	(179,104)
Issuance of ordinary shares for initial public offering, net of issuance costs	450,085	4	450,081
Conversion of convertible redeemable preferred shares to ordinary shares	240,434	2	240,432
Issuance of ordinary shares relating to private placement for Genscript	12,000		12,000
Equity-settled share-based compensation expense	668			668
Ending balance at Jun. 30, 2020	401,001	26	706,421	2,644	(1,704)	(306,386)
Beginning balance at Dec. 31, 2019	(122,869)	20	3,908	1,976	(1,491)	(127,282)
Other comprehensive income:
Issuance of ordinary shares for initial public offering, net of issuance costs	450,085		450,081
Issuance of ordinary shares relating to private placement for Genscript	12,000		12,000
Ending balance at Dec. 31, 2020	280,255	27	708,306	6,314	(3,633)	(430,759)
Loss for the period	(172,483)					(172,483)
Other comprehensive income:
Exchange differences on translation of foreign operations	3,305				3,305
Total comprehensive income/(loss) for the period	(169,178)				3,305	(172,483)
Issuance of ordinary shares relating to private placement for an institutional investor	218,300	2	218,298
Exercise of share options	2,509		3,280	(771)
Reclassification of vested restricted share units			200	(200)
Equity-settled share-based compensation expense	8,033			8,033
Ending balance at Jun. 30, 2021	$ 339,919	$ 29	$ 930,084	$ 13,376	$ (328)	$ (603,242)

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Statement Of Changes In Equity [Abstract]
Reserve	$ 339,890,000	$ 280,228,000	$ 400,975,000

UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax	$ (172,482)	$ (182,813)
Adjustments for:
Finance income	(227)	(1,808)
Finance costs	90	4,079
Reversal of the impairment of trade receivables	(22)	(9)
Write-down of inventories to net realizable value	6
Loss from disposal of property, plant and equipment	937	1
Depreciation of property, plant and equipment	5,391	4,421
Amortisation of intangible assets	596	54
Depreciation of right-of-use assets	721	694
Fair value loss of warrant liability	1,600
Fair value loss of convertible redeemable preferred shares		79,984
Fair value gains on financial assets at fair value change through profit or loss		(39)
Foreign currency exchange loss, net	703	27
Equity-settled share-based compensation expenses	8,033	668
Deferred government grant	(144)
Adjustments to reconcile profit (loss)	(154,798)	(94,741)
Decrease in trade receivables	60,000	30,000
Decrease/(increase) in prepayments, other receivables and other assets	(1,081)	387
Increase in other non-current assets	(912)
(Increase)/Decrease in inventories	94	(511)
Government grant received	79
(Decrease)/increase in trade and notes payables	5,763	(2,610)
(Decrease)/increase in other payables and accruals	27,649	(12,597)
Decrease in contract liabilities	(21,318)	(23,033)
Decrease of pledged short-term deposits, net	128
Cash used in operations	(84,396)	(103,105)
Income tax paid	(1)
Finance income received	145	529
Interest on lease payments	(73)	(105)
Net cash flows used in operating activities	(84,325)	(102,681)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(28,926)	(26,220)
Purchase of intangible assets	(2,424)	(530)
Proceeds from disposal of items of property, plant and equipment	20
Purchase of financial assets at fair value through profit or loss		(18,504)
Cash received from withdrawal of financial assets at fair value through profit or loss		18,504
Cash receipts from investment income		39
Purchase of financial investment measured at amortized cost	(29,849)
Addition of time deposits	(204,644)
Decrease in time deposits	80,000
Net cash flows used in investing activities	(185,823)	(26,711)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayment of cash advances from related parties		(4)
Proceeds from convertible redeemable preferred shares		160,450
Proceeds from issuance of ordinary shares for Initial public offering, net of issuance costs		450,085
Proceeds from issuance of ordinary shares relating to private placement for an institutional investor	300,000
Payments of expenses for issuance convertible redeemable preferred shares		(250)
Proceeds from exercise of share option	2,509
Principal portion of lease payments	(550)	(1,723)
Net cash flows from financing activities	301,959	608,558
NET INCREASE IN CASH AND CASH EQUIVALENTS	31,811	479,166
Effect of foreign exchange rate changes, net	715	(139)
Cash and cash equivalents at beginning of period	455,689	83,364
CASH AND CASH EQUIVALENTS AT END OF PERIOD	488,215	562,391
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS
Cash and bank balances	663,115	638,206
Less: Pledged short-term deposits	256	256
Time deposits	174,644	75,559
Cash and cash equivalents as stated in the statement of financial position	488,215	562,391
Cash and cash equivalents as stated in the statement of cash flows	$ 488,215	$ 562,391

Corporate Information

6 Months Ended

Jun. 30, 2021

Disclosure Of Significant Investments In Subsidiaries [Abstract]

Corporate Information

1. CORPORATE INFORMATION

Legend Biotech Corporation (the “Company”) was incorporated on May 27, 2015 as an exempted company in the Cayman Islands with limited liability under the Companies Law of the Cayman Islands. The registered office address of the Company is PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grant Cayman KY1-1002, Cayman Islands.

The Company is an investment holding company. The Company’s subsidiaries are principally engaged in research and development of biological products.

In the opinion of the Directors, the parent company of the Company is Genscript Biotech Corporation (“Genscript”), which was incorporated in the Cayman Islands on May 21, 2015 and listed on the main board of Hong Kong Stock Exchange since December 30, 2015.

Basis of Preparation

6 Months Ended

Jun. 30, 2021

Basis Of Preparation [Abstract]

Basis of Preparation

2.1. BASIS OF PREPARATION

The unaudited interim condensed consolidated financial statements of the company and its subsidiaries (collectively referred to as the “Group”) for the six months ended June 30, 2021 have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting (“IAS34”) issued by the International Accounting Standards Board (“IASB”).

The accounting policies and basis of preparation adopted in the preparation of these unaudited interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s financial statements for the year ended December 31, 2020, except for the adoption of new standards effective as of January 1, 2021 set out below. The Group has not early adopted any other standards, interpretation or amendments that has been issued but is not yet effective.

In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all normal recurring adjustments necessary to present fairly the financial position, operating results and cash flows of the Company for each of the periods presented. The results of operations for the six months ended June 30, 2021 are not necessarily indicative of results to be expected for any other interim periods or for the year ended December 31, 2021. The condensed consolidated statement of financial position as of December 31, 2020 was derived from the audited consolidated financial statements at that date but does not include all of the disclosures required by IFRS for annual financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements for the years ended December 31, 2020.

2.2.	NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS ADOPTED BY THE GROUP

In the six months ended June 30, 2021, the Group has applied, for the first time, the following new and revised international financial reporting standards (“IFRS”) issued by the IASB that are mandatorily effective for the period.

Amendments to IFRS 9,
IAS 39, IFRS 7,
IFRS 4 and IFRS 16	Interest Rate Benchmark Reform – Phase 2

The prospective adoption of the above new and revised IFRSs does not have a material effect on the Group’s interim condensed consolidated financial statements.

Operating Segment Information

6 Months Ended

Jun. 30, 2021

Disclosure Of Operating Segments [Abstract]

Operating Segment Information

3. OPERATING SEGMENT INFORMATION

IFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reporting about components of the Group that are regularly reviewed by the chief operating decision-maker in order to allocate resources to segments and to assess their performance. The information reported to the directors of the Company, who are the chief operating decision makers, for the purpose of resource allocation and assessment of performance does not contain discrete operation segment financial information and the directors reviewed the financial results of the Group as a whole. Therefore, no further information about the operating segment is presented.

Geographic information

(a) Revenue from external customers

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
North America		23,146		33,915

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
China		43,953		48,370
United States		78,022		98,455
Other countries		6,174		7,466
Total		128,149		154,291

The non-current asset information above is based on the locations of assets.

Information about major customer

Revenue of US$23,146,000 and US$33,915,000 for the six months ended June 30, 2020 and 2021, respectively, was derived from sales to a single customer.

Revenue, Other Income and Gains

6 Months Ended

Jun. 30, 2021

Revenue Other Income And Gains [Abstract]

Revenue, Other Income and Gains

4. REVENUE, OTHER INCOME AND GAINS

An analysis of revenue is as follows:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Revenue from contracts with customers
License and collaboration revenue
- Licensing of intellectual property		—		1,122
- JSC service		23,146		32,793
Total		23,146		33,915

Revenue from the licensing of intellectual property is recognized at a point in time and revenue from JSC service is recognized overtime.

The following table shows the amounts of revenue recognized in the current reporting period that were included in the contract liabilities at the beginning of the reporting period and recognized from performance obligations satisfied in previous periods:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Revenue recognized that was included in contract liabilities at the beginning of the reporting period:
License and collaboration revenue
- JSC service		23,146		27,408

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Revenue recognized from performance obligation satisfied in previous periods:
License and collaboration revenue
- Licensing of intellectual property		—		1,122
- JSC service		—		4,615
		—		5,737

(i) Performance obligations

The amounts of transaction prices allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at December 31, 2020 and June 30, 2021 are as follows:

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Amounts expected to be recognized as revenue:
Within 1 year		55,014		56,139
1 - 2 years		55,014		56,139
2 - 3 years		55,014		56,139
3 - 4 years		55,014		56,139
After 4 years		110,029		84,211
		330,085		308,767

The amounts of transaction prices allocated to the remaining performance obligations which are expected to be recognised as revenue after one year relate to JSC service, of which the performance obligations are to be satisfied over the collaboration period, which is estimated to be 9 years. The amounts disclosed above do not include variable consideration which is constrained.

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Other income and gains
Government grants*		1,945		1,323
Finance income		1,808		227
Fair value gains on financial assets at fair value change through profit or loss		39		—
Rental income		4		8
Others**		—		832
		3,796		2,390

*	The amount represents subsidies received from local government authorities to support the Group’s business. There were no unfulfilled conditions and other contingencies attached to these government grants.

**	The amount mainly represents reimbursement of depositary fees that are related to the establishment and maintenance of the ADR program.

Loss Before Tax

6 Months Ended

Jun. 30, 2021

Profit Loss [Abstract]

Loss Before Tax

5. LOSS BEFORE TAX

The Group’s loss before tax is arrived at after charging/(crediting):

			Six months ended June 30,
			2020			2021
	Notes		US$’000			US$’000
			(Unaudited)			(Unaudited)
Reversal for the impairment of trade receivables, net		9		(9	)		(22	)
IPO expenses				1,439			—
Employee benefit expense:
Wages and salaries				30,794			47,303
Pension scheme contributions (defined contribution schemes)				436			1,759
Equity-settled share-based compensation expense				668			8,033

Income Tax

6 Months Ended

Jun. 30, 2021

Major Components Of Tax Expense Income [Abstract]

Income Tax

6. INCOME TAX

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Cayman Islands

Under the current laws of the Cayman Islands, the Company is not subject to tax on income or capital gains.

British Virgin Islands

Under the current laws of the British Virgin Islands (“BVI”), Legend Biotech Limited (“Legend BVI”) is not subject to tax on income or capital gains. Additionally, upon payments of dividends by the Group’s subsidiaries incorporated in the British Virgin Islands to their shareholders, no withholding tax will be imposed.

Hong Kong

Under the current laws of Hong Kong, the subsidiary which operates in Hong Kong is subject to a corporate income tax (“CIT”) at a rate of 16.5% on the taxable income. Under the Hong Kong tax law, the subsidiaries in Hong Kong are exempted from income tax on their foreign derived income and there are no withholding taxes in Hong Kong on remittance of dividends.

United States of America

Under the current laws of the United States of America (“USA”), the subsidiary which operates in the United States of America is subject to federal tax at a rate of 21% and state tax at a rate of 11.5% in New Jersey. Dividends payable by the Group’s US entity, to non US resident enterprises shall be subject to 30% withholding tax, unless the respective non US resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with US that provides for a reduced withholding tax rate or an exemption from withholding tax.

Ireland

Under the current laws of Ireland, the subsidiary which operates in Ireland is subject to CIT at a rate of 12.5% on its taxable trading income. Any non-trading income is subject to CIT at a rate of 25%. Dividend withholding tax is imposed on distributions made by Irish companies at a rate of 25% with many exemptions provided.

Mainland China

Pursuant to the Corporate Income Tax Law of the PRC and the respective regulations (the “CIT Law”), the subsidiaries which operate in Mainland China are subject to CIT at a rate of 25% on the taxable income. The applicable income tax rate was 25%. Dividends, interests, rent or royalties payable by the Group’s PRC entities, to non PRC resident enterprises, and proceeds from any such non-resident enterprise investor’s disposition of assets (after deducting the net value of such assets) shall be subject to 10% CIT, namely withholding tax, unless the respective non PRC resident enterprise’s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.

Netherlands

Under the current laws of Netherlands, the subsidiary which operates in Netherlands is subject to CIT at a rate of 25% on the taxable income. A tax rate of 16.5% applies to the first EUR200,000 of taxable income. The statutory withholding tax rate for dividends is 15% while several exemptions and reductions can apply.

	Six months ended June 30,
	2020			2021
	US$’000			US$’000
	(Unaudited)			(Unaudited)
Current – United States of America		(3,709	)		—
Current – Elsewhere		—			1
Total tax charge for the year		(3,709	)		1

Loss per Share Attributable to Ordinary Equity Holders of the Parent

6 Months Ended

Jun. 30, 2021

Basic Earnings Per Share [Abstract]

Loss per Share Attributable to Ordinary Equity Holders of the Parent

7. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 207,775,944 and 271,684,977 in issue during the six months ended June 30, 2020 and 2021, respectively.

The calculation of the diluted earnings per share amount is based on the loss for the period attributable to ordinary equity holders of the parent. The weighted average number of ordinary shares used in the calculation is the number of ordinary shares in issue during the period, as used in the basic earnings per share calculation, and the weighted average number of ordinary shares assumed to have been issued at no consideration on the deemed exercise of all dilutive potential ordinary shares into ordinary shares.

No adjustment was made to the basic loss per share amounts presented for the six months ended June 30, 2020 and 2021 in respect of a dilution as the impact of the outstanding share options had an anti-dilutive effect on the basic loss per share amounts presented.

The calculations of basic and diluted loss per share are based on:

	Six months ended June 30,
	2020			2021
	US$’000			US$’000
	(Unaudited)			(Unaudited)
Losses
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation		(179,104	)		(172,483	)

	Number of shares Six months ended June 30,
	2020		2021
	(Unaudited)		(Unaudited)
Shares
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation		207,775,944		271,684,977

Property, Plant and Equipment

6 Months Ended

Jun. 30, 2021

Disclosure Of Property Plant And Equipment [Abstract]

Property, Plant and Equipment

8. PROPERTY, PLANT AND EQUIPMENT

During the six months ended June 30, 2021, the Group acquired items of property, plant and equipment with a cost of US$28,822,000 (for the six months ended June 30, 2020: US$25,250,000). Among which, the charge from a customer under a license and collaboration agreement amounted to US$4,204,000 (for the six months ended June 30, 2020: US$7,294,000).

Trade Receivables

6 Months Ended

Jun. 30, 2021

Trade And Other Receivables [Abstract]

Trade Receivables

9. TRADE RECEIVABLES

	December 31, 2020			June 30, 2021
	US$’000			US$’000
				(Unaudited)
Trade receivables		75,000			15,000
Less: Impairment of trade receivables		(22	)		—
		74,978			15,000

The Group’s trading terms with its customers are mainly on credit. The credit period is 30 to 90 days. The Group seeks to maintain strict control over its outstanding receivables and overdue balances are reviewed regularly by management. Trade receivables are non-interest-bearing. The Group has concentration of credit risk as 100% of trade receivables were due from one single customer under a license and collaboration agreement as at June 30, 2021.

Movements in the loss allowance for impairment of trade receivables were as follows:

	Total
	US$’000
At January 1, 2020		9
Impairment losses reversed		(9	)
Impairment losses recognised		22
At December 31, 2020		22
At January 1, 2021		22
Impairment losses reversed		(22	)
Impairment losses recognised		—
At June 30, 2021 (Unaudited)		—

Financial Investment Measured at Amortized Cost

6 Months Ended

Jun. 30, 2021

Disclosure Of Financial Investment Measured At Amortized Cost [Abstract]

Financial Investment Measured at Amortized Cost

10. FINANCIAL INVESTMENT MEASURED AT AMORTIZED COST

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)

Financial investment measured at amortized cost		—		29,849

Financial investment measured at amortized cost was related to commercial paper issued by a financial institution with principal amount of US$30,000,000, discounted bid yield of 0.5% per annum and one year maturity date as June 1, 2022.

Cash and Cash Equivalents and Pledged Deposits

6 Months Ended

Jun. 30, 2021

Disclosure Of Cash And Cash Equivalents And Pledged Deposits [Abstract]

Cash and Cash Equivalents and Pledged Deposits

11. CASH AND CASH EQUIVALENTS AND PLEDGED DEPOSITS

	December 31, 2020			June 30, 2021
	US$’000			US$’000
				(Unaudited)
Cash and bank balances		506,073			663,115
Less: pledged short-term deposits		(384	)		(256	)
time deposits		(50,000	)		(174,644	)
Cash and cash equivalents		455,689			488,215
Denominated in USD		451,165			472,722
Denominated in RMB		4,335			12,614
Denominated in EUR		189			2,879
Cash and cash equivalents		455,689			488,215

The cash and bank balances of the Group denominated in Renminbi (“RMB”) amounted to US$4,335,000 and US$12,614,000 in the condensed consolidated statements of financial position as at December 31, 2020 and June 30, 2021, respectively. The RMB is not freely convertible into other currencies, however, under Mainland China’s Foreign Exchange Control Regulations and Administration of Settlement, Sale and Payment of Foreign Exchange Regulations, the Group is permitted to exchange RMB for other currencies through banks authorised to conduct foreign exchange business.

The pledged deposit as at June 30, 2021 was pledged for credit card facilities. The pledged deposit as at December 31, 2020 was pledged for issuing bank notes payables to suppliers of the Group and for credit card facilities.

Cash at banks earns interest at floating rates based on daily bank deposit rates. The bank balances are deposited with creditworthy banks with no recent history of default. The carrying amounts of the cash and cash equivalents approximate to their fair values.

Trade and Notes Payables

6 Months Ended

Jun. 30, 2021

Trade And Other Payables [Abstract]

Trade and Notes Payables

12. TRADE AND NOTES PAYABLES

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Trade payables		4,911		11,001
Notes payables		327		—
		5,238		11,001

The trade payables are non-interest-bearing and are normally settled on a 60-day term.

As at December 31, 2020 and June 30, 2021, included in the Group’s trade payables are amounts due to the Group’s related parties of US$2,103,000 and US$6,148,000, respectively (note 19).

Convertible Redeemable Preferred Shares

6 Months Ended

Jun. 30, 2021

Disclosure Of Classes Of Share Capital [Abstract]

Convertible Redeemable Preferred Shares

13. CONVERTIBLE REDEEMABLE PREFERRED SHARES

On March 30, 2020 and on April 16, 2020, the Company issued a total of 20,591,629 Series A convertible redeemable preferred shares (the “Series A Preference Shares”) to independent third parties, at the price of US$7.792 per share for an aggregate purchase consideration of US$160,450,000.

The key terms of the Series A Preference Shares are summarised as follows:

(1) Dividends rights

Each Series A Preference Shares holder is entitled to dividends at the rate of 8% of the Series A original issue price per annum per share shall accrue on such Series A Preference Shares. Such dividends (i) will be declared by the board of directors and paid to the holders of Series A Preference Shares each fiscal quarter, or (ii) if not declared and, with respect to any fiscal quarter, paid to the holders of Series A Preference Shares within thirty days after such fiscal quarter, such undeclared and unpaid dividends will accrue day to day from the last day of such fiscal quarter, will be cumulative and compound annually, and will only be paid upon a redemption or liquidation event or converted into ordinary shares upon an initial public offering.

(2) Conversion rights

Optional conversion

Each Series A Preference Share is convertible, at the option of the holder, at any time after the date of issuance of such Series A Preference Share, into such number of fully paid and non-assessable ordinary shares as is determined by dividing the Series A original issue price, by a conversion price equal to the lower of (i) the conversion price at the time in effect for such Series A Preference Share and (ii) the price per share that equals the lowest net price per ordinary share received by the Company in a public offering that is not a Qualified IPO.

Automatic conversion

Each Series A Preference Share will be automatically converted upon the closing of a Qualified IPO into a number of ordinary shares as is determined by dividing the Series A original issue price by a conversion price is equal to the lower of (i) the conversion price at the time in effect for such Series A Preference Share and (ii) the price per share that equals 90% of the lowest net price per ordinary share received by the Company in the Qualified IPO.

(3) Redemption rights

At any time on or after the occurrence of a Trigger Event (as defined below), each investor may require the Company to redeem the Series A Preference Shares issued to the investor and require the Company to immediately pay the investor an amount equal to the redemption price, plus 8% annualized. A “Trigger Event” means the occurrence of one or more of the following events: (A) as of September 30, 2021, the Company has not consummated a qualified IPO, (B) the Company consummates a non-Qualified IPO, (C) the License Agreement (i) is terminated as a result of a material breach by any party thereto or (ii) is amended in such a way that with (or without) the passage of time would reasonably be expected to adversely affect the value of the Company or the Series A Preference Shares in any material respect and (D) there occurs or it is discovered that there is a material adverse issue with respect to the patents, know-how and all other intellectual property owned or controlled by the Company or its affiliates and licensed to a customer under a license and collaboration agreement, which is not capable of being cured within a reasonable period.

(4) Liquidation

Upon any liquidation, dissolution or winding up of the Company (collectively, a “Liquidation Event”), before any distribution or payment shall be made to the holders of any Ordinary Shares, the holders of Series A Preference Shares will be entitled to be paid out of the assets of the Company legally available for distribution for each Series A Preference Share, an amount per Series A Preference Share equal to the sum of (i) the Series A Original Issue Price, plus (ii) any accrued but unpaid Dividends on each Series A Preference Share. If, upon any such Liquidation Event, the assets of the Company will be insufficient to make payment in full to all holders of Series A Preference Shares, then such assets (or consideration) will be distributed among the holders of Series A Preference Shares at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled.

All Series A Preferred Shares were converted into ordinary shares of the Company and all accrued but unpaid dividends were settled in the form of ordinary shares upon qualified IPO in June 2020. A fair value loss of $80.0 million was recorded for the six months ended June 30, 2020 due to change in fair value upon conversion.

Warrant Liability

6 Months Ended

Jun. 30, 2021

Warrant Liability [Abstract]

Warrant Liability

14. WARRANT LIABILITY

On May 13, 2021, the Company entered into a subscription agreement with an institutional investor relating to the offer and sale of 20,809,850 ordinary shares of the Company, par value US$0.0001 per share, in a private placement at a purchase price of $14.41625 per ordinary share (the “PIPE Offering”). The total proceeds from the PIPE Offering is US$300,000,000. Pursuant to the subscription agreement, the Company also agreed to issue and sell concurrently with the PIPE offering a warrant (the “Warrant”) exercisable for up to an aggregate of 10,000,000 ordinary shares (such transaction together with the PIPE Offering, the “Transactions”). The Transactions have been closed on May 21, 2021(the “Closing Date”). The Warrant will be exercisable, in whole or in part, at an exercise price of $20.00 per ordinary share. The Warrant is exercisable after the Closing Date and prior to the two-year anniversary of the Closing Date.

The Warrant is accounted for as a financial liability because the Warrant may be net share settleable at the holder’s option. The fair value of the warrant liability is assessed at US$81.7 million and is recognized upon closing of the transaction. As of June 30, 2021, its fair value is assessed at US$83.3 million. A fair value loss of US$1.6 million is recorded for the six months ended June 30, 2021 due to change in fair value.

The movement of the warrant liability is set out as below:

	Total
	US$’000
At January 1, 2021		—
Issuance of the warrant liability		81,700
Fair value loss of the warrant liability		1,600
At June 30, 2021		83,300

Interest-Bearing Loans and Borrowings

6 Months Ended

Jun. 30, 2021

Disclosure Of Detailed Information About Borrowings [Abstract]

Interest-Bearing Loans and Borrowings

15. INTEREST-BEARING LOANS AND BORROWINGS

Effective interest rate (%)

Maturity

June 30,

2021

US$’000

(Unaudited)

Non-current

Loans from a collaborator

2.74

No specific maturity date

17,310

Pursuant to the license and collaboration agreement entered into with a collaborator, the Company is entitled to receive funding advances from the collaborator when certain operational conditions are met. As a result, the Company took a funding advance amounted to $17.3 million by reducing the same amount of other payables due to the collaborator (the “Funding Advance”) on June 18, 2021.

This Funding Advance is accounted for as an interest-bearing borrowing funded by the collaborator, constituted by a principal and applicable interests upon such principal. The interest rate is based on the average annual London Interbank Offered Rate (LIBOR) for U.S. Dollars as reported in the Wall Street Journal on a quarterly basis on the due date, plus 250 basis points, calculated on the number of days from the date on which the Company applied such borrowings. For this $17.3 million of Funding Advance, interest started to accrue from June 18, 2021.

Pursuant to the terms of the license and collaboration agreement, the collaborator may recoup the aggregate amount of Funding Advance together with interest thereon from Company’s share of pre-tax profits for the first profitable year. The Company’s management estimated the loan will not be recouped by the collaborator within one year, and thus the loan was classified as a long-term liability.

Share Capital and Share Premium

6 Months Ended

Jun. 30, 2021

Disclosure Of Classes Of Share Capital [Abstract]

Share Capital and Share Premium

16. SHARE CAPITAL AND SHARE PREMIUM

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Authorised:
500,000,000 ordinary shares of US$0.0001 each		50		50
Issued and fully paid:
266,010,256 and 289,428,096 ordinary shares of US$0.0001 each		27		29

A summary of movements in the Company’s share capital and share premium is as follows:

	Number of shares in issue		Share capital		Share premium		Total
			US$’000		US$’000		US$’000
At December 31, 2019 and January 1, 2020		200,000,000		20		3,908		3,928
Issuance of ordinary shares for initial public offering, net of issuance costs		42,377,500		4		450,081		450,085
Issuance of ordinary shares for conversion of preferred shares		20,907,282		2		240,432		240,434
Issuance of ordinary shares for private placement by Genscript		1,043,478		—		12,000		12,000
Exercise of share option		1,681,996		1		1,885		1,886
At December 31, 2020		266,010,256		27		708,306		708,333


	Number of shares in issue		Share capital		Share premium		Total
			US$’000		US$’000		US$’000
At December 31, 2020 and January 1, 2021		266,010,256		27		708,306		708,333
Issuance of ordinary shares for an institutional investor		20,809,850		2		218,298		218,300
Exercise of share option		2,590,596		—		3,280		3,280
Vesting of RSU		17,394		—		200		200
At June 30, 2021 (Unaudited)		289,428,096		29		930,084		930,113

Notes to the Consolidated Statement of Cash Flows

6 Months Ended

Jun. 30, 2021

Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]

Notes to the Consolidated Statement of Cash Flows

17. NOTES TO THE CONSOLIDATED STATEMENT OF CASH FLOWS

(a) Major non-cash transactions

For the six months ended June 30, 2020, the Group had non-cash decrease to right-of-use assets of US$924,000 and lease liabilities of US$924,000, in respect of lease arrangements for buildings.

For the six months ended June 30, 2020, the Group had non-cash additions to finance costs of US$3,764,000 and other payable of US$3,764,000 relating to issuance costs for convertible redeemable preferred shares. As at June 30, 2020, the Group also had non-cash financing proceeds from the issuance of ordinary shares relating to a private placement for Genscript amounted to US$12,000,000, which was included in other receivables. The cash proceed is subsequently received in full.

For the six months ended June 30, 2021, the Group had non-cash additions to interest-bearing loans and borrowings of US$17,310,000 which was received through the deduction of other payables to collaborator.

(b) Changes in liabilities arising from financing activities

	Convertible redeemable preferred shares			Other payable to related parties			Lease liabilities
	US$’000			US$’000			US$’000
At January 1, 2020		—			4			6,085
Decrease of lease liabilities		—			—			(924	)
Changes from financing cash flows		160,450			(4	)		(1,723	)
Fair value loss of the Series A Preferred Shares		79,984			—			—
Conversion to ordinary shares		(240,434	)		—			—
Interest expense		—			—			105
Interest paid classified as operating cash flows		—			—			(105	)
Foreign exchange movement		—			—			(5	)
At June 30, 2020 (Unaudited)		—			—			3,433
At January 1, 2021		—			—			3,373
Changes from financing cash flows		—			—			(550	)
Interest expense		—			—			73
Interest paid classified as operating cash flows		—			—			(73	)
Foreign exchange movement		—			—			(24	)
At June 30, 2021 (Unaudited)		—			—			2,799

The total cash outflow for leases included in the statement of cash flows is as follows:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Right-of-use assets
Within operating activities		105		73
Within financing activities		1,723		550
Short-term leases		43		105
		1,871		728

Capital Commitments

6 Months Ended

Jun. 30, 2021

Capital Commitments [Abstract]

Capital Commitments

18. CAPITAL COMMITMENTS

The Group had the following capital commitments as at June 30, 2021:

Less than

one year

(Unaudited)

Construction in progress

23,954

Related Party Transactions

6 Months Ended

Jun. 30, 2021

Disclosure Of Transactions Between Related Parties [Abstract]

Related Party Transactions

19. RELATED PARTY TRANSACTIONS

Company		Relationship
Nanjing GenScript Biotech Co., Ltd.		Company controlled by the ultimate holding company
Jiangsu Genscript Biotech Co., Ltd.		Company controlled by the ultimate holding company
Genscript (HongKong) Ltd.		Company controlled by the ultimate holding company
Genscript USA Incorporated		Company controlled by the ultimate holding company
Genscript USA Holdings Inc		Company controlled by the ultimate holding company
CUSTOMARRAY, INC.		Company controlled by the ultimate holding company

(a)

In addition to the transactions detailed elsewhere in these interim condensed consolidated financial statements, the Group had the following transactions with related parties during the period:

(i)

Purchases from related parties:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Nanjing GenScript Biotech Co., Ltd.		1,664		5,858
Genscript USA Incorporated		458		298
Jiangsu Genscript Biotech Co., Ltd.		13		124
		2,135		6,280

The transactions were made according to the terms and conditions agreed with related parties.

(ii)

Management fee:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Genscript USA Incorporated		95		21
Nanjing GenScript Biotech Co., Ltd.		—		95
		95		116

The management fee was charged by related parties based on the cost of services provided.

(iii)

Shared services:

During the six months ended June 30, 2020 and 2021, Nanjing GenScript Biotech Co., Ltd.. provided certain accounting, legal, IT and administrative shared services to the Group for the consideration of US$1,998,000 and US$1,040,000, respectively.

(iv)

Repayment of cash advances from related parties:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Genscript (HongKong) Ltd.		4		—

The above cash advances from related parties were unsecured, interest free and repayable on demand.

(v)

Purchase of equipment

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Nanjing GenScript Biotech Co., Ltd.		52		—

The purchase of equipment was made at their respective carrying value.

(vi)

Compensation fee for termination of service agreement:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Jiangsu Genscript Biotech Co., Ltd.		—		2,649

In May 2021, pursuant to a settlement agreement between the Group and Jiangsu Genscript Biotech Co., Ltd., the Group incurred compensation charges for the termination of a service agreement related to the design and construction of a lab facility.

(b)

Outstanding balances with related parties:

The Group had the following significant balances with its related parties:

(i)

Due from related parties

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Other Receivables
Genscript USA Incorporated		6		12
Nanjing GenScript Biotech Co., Ltd.		14		32
Jiangsu Genscript Biotech Co., Ltd.		—		1
CUSTOMARRAY, INC.		—		1
		20		46

(ii)

Due to related parties

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Trade Payables
Nanjing GenScript Biotech Co., Ltd.		1,547		5,541
Genscript USA Incorporated		555		483
Jiangsu Genscript Biotech Co., Ltd.		1		124
		2,103		6,148

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Other Payables
Nanjing GenScript Biotech Co., Ltd.		3,736		2,137
Genscript USA Incorporated		—		12
Jiangsu Genscript Biotech Co., Ltd.		—		3,803
		3,736		5,952

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Lease Liabilities
Genscript USA Holdings Inc		582	297
Nanjing GenScript Biotech Co., Ltd.		351	391
		933	688

Except for lease liabilities with incremental borrowing rates between 2.00% and 7.28% and repayable over 5 years, other related party balances are unsecured and repayable on demand.

(c)

Compensation of key management personnel of the Group:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Short-term employee benefits		913		1,007
Equity-settled share-based compensation expense		306		1,125
		1,219		2,132

Financial Instruments by Category

6 Months Ended

Jun. 30, 2021

Disclosure Of Financial Instruments [Abstract]

Financial Instruments by Category

20. FINANCIAL INSTRUMENTS BY CATEGORY

The carrying amounts of each of the categories of financial instruments as at the end of each of the reporting periods are as follows:

As at December 31, 2020

Financial assets

	Financial assets at amortised cost
	US$’000
Trade receivables		74,978
Financial assets included in prepayments, other receivables and other assets		344
Time deposits		50,000
Pledged deposits		384
Cash and cash equivalents		455,689
		581,395

Financial liabilities

	Financial liabilities at amortised cost
	US$’000
Trade and notes payables		5,238
Financial liabilities included in other payables and accruals		85,559
Lease liabilities		3,373
		94,170

As at June 30, 2021

Financial assets

	Financial assets at amortised cost
	US$’000
	(Unaudited)
Trade receivables		15,000
Financial assets included in prepayments, other receivables and other assets		487
Financial investment measured at amortized cost		29,849
Time deposits		174,644
Pledged deposits		256
Cash and cash equivalents		488,215
		708,451

Financial liabilities

	Financial liabilities at fair value through profit and loss		Financial liabilities at amortised cost
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Trade and notes payables		—		11,001
Warrant liability		83,300		—
Financial liabilities included in other payables and accruals		—		24,756
Interest-bearing loans and borrowings		—		17,310
Lease liabilities		—		2,799
		83,300		55,866

Fair Value and Fair Value Hierarchy of Financial Instruments

6 Months Ended

Jun. 30, 2021

Disclosure Of Fair Value Of Financial Instruments [Abstract]

Fair Value and Fair Value Hierarchy of Financial Instruments

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

As at December 31, 2020 and June 30, 2021, the fair values of the Group’s financial assets or liabilities approximated to their respective carrying amounts.

Management has assessed that the fair values of cash and cash equivalents, pledged deposits, time deposits, financial assets included in prepayments, other receivables and other assets, trade receivables, trade payables and financial liabilities included in other payables and accruals approximate to their carrying amounts largely due to the short-term maturities of these instruments.

The Group’s finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance department reports directly to the finance manager. At each reporting date, the finance department analyzed the movements in the values of financial instruments and determined the major inputs applied in the valuation. The valuation was reviewed and approved by the finance manager. The valuation process and results are discussed with the directors once a year for annual financial reporting.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale.

Fair value hierarchy

All financial instruments for which fair value is recognised or disclosed are categorised within the fair value hierarchy, based on the lowest level input that is significant to the fair value measurement as a whole, as follows:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. There were no changes in the Group’s valuation processes, valuation techniques, and types of inputs used in the fair value measurements during the period.

The following table illustrates the fair value measurement hierarchy of the Group’s financial instruments:

Liability measured at fair value:

As at June 30, 2021 (Unaudited)
	Fair value measurement using
	Quoted prices in active markets (Level 1)		Significant observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
	US$’000		US$’000		US$’000		US$’000
Warrant liability:		—		83,300		—		83,300
		—		83,300		—		83,300

The following table lists the inputs to the binominal model used for the fair value valuation of warrant liability:

	June 30, 2021
	(Unaudited)
Underlying stock price		US$20.53
Volatility		75.6%
Risk free rate		0.25%
Dividend		0%

During the six months ended June 30, 2020 and 2021, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities.

Financial Risk Management Objectives and Policies

6 Months Ended

Jun. 30, 2021

Disclosure Of Financial Instruments [Abstract]

Financial Risk Management Objectives and Policies

22. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The Group’s principal financial instruments comprise cash and cash equivalents, pledged deposits, financial investment measured at amortized cost, financial assets at fair value through profit or loss, prepayments, other receivables and other assets, financial liabilities at fair value through profit or loss, financial liabilities included in other payables and accruals and interest-bearing loans and borrowings. The main purpose of these financial instruments is to raise finance for the Group’s operations. The Group has various other financial assets and liabilities such as trade receivables and trade payables, which arise directly from its operations.

The main risks arising from the Group’s financial instruments are foreign currency risk, credit risk and liquidity risk. The board of directors reviews and agrees policies for managing each of these risks and they are summarised below.

Foreign currency risk

The Group has transactional currency exposures. Such exposures arise from sales or purchases by operating units in currencies other than the units’ functional currencies. Approximately 36% of the Group’s sales were denominated in currencies other than the functional currencies of the operating units making the sale in the six months ended June 30, 2021 (Six months ended June 30, 2020: 23%).

As at December 31, 2020 and June 30, 2021, the Group has no outstanding foreign currency forward exchange contract. At present, the Group does not intend to seek to hedge its exposure to foreign exchange fluctuations. However, management constantly monitors the economic situation and the Group’s foreign exchange risk profile and will consider appropriate hedging measures in the future should the need arise.

The following table demonstrates the sensitivity at the end of the reporting period to a reasonably possible change in the EUR and RMB exchange rate against US$, with all other variables held constant, of the Group’s loss before tax (due to changes in the fair values of monetary assets and liabilities).

	Increase/ (decrease) in the rate of foreign currency	Decrease/ (increase) in loss before tax
	%	US$’000
		(Unaudited)
Six months ended June 30, 2021
If US$ strengthens against RMB	5		1,011
If US$ weakens against RMB	-5		(1,011	)
If US$ strengthens against EUR	5		(680	)
If US$ weakens against EUR	-5		680

Six months ended June 30, 2020
If US$ strengthens against RMB	5		473
If US$ weakens against RMB	-5		(473	)
If US$ strengthens against EUR	5		(501	)
If US$ weakens against EUR	-5		501

Credit risk

The Group trades only with recognised and creditworthy third parties. It is the Group’s policy that all customers who wish to trade on credit terms are subject to credit verification procedures. In addition, receivable balances are monitored on an ongoing basis and the Group’s exposure to bad debts is not significant. For transactions that are not denominated in the functional currency of the relevant operating unit, the Group does not offer credit terms without the specific approval of the Head of Credit Control.

The credit risk of the Group’s other financial assets, which comprise cash and cash equivalents, pledged deposits, financial investment measured at amortized cost and other receivables, arises from default of the counterparty, with a maximum exposure equal to the carrying amounts of these instruments. Further quantitative data in respect of the Group’s exposure to credit risk arising from trade receivables are disclosed in note 9 to the unaudited interim condensed consolidated financial statements.

Since the Group trades only with recognized and creditworthy third parties, there is no requirement for collateral. Concentrations of credit risk are managed by debtor. The Group had certain concentrations of credit risk with respect to trade receivables, which are disclosed in note 9 to the unaudited interim condensed consolidated financial statements.

Liquidity risk

The Group monitors its risk to a shortage of funds using a recurring liquidity planning tool. This tool considers the maturity of both its financial investments and financial assets (e.g., trade receivables and other financial assets) and projected cash flows from operations.

The maturity profile of the Group’s financial liabilities as at the end of the reporting period, based on contractual undiscounted payments, is as follows:

As at December 31, 2020

	Less than 1 years US$’000		Over 1 years US$’000		Total US$’000
Trade payables		5,238		—		5,238
Other payables and accruals		85,559		—		85,559
Lease liabilities		1,464		2,099		3,563
		92,261		2,099		94,360

As at June 30, 2021

	Less than 1 years US$’000		Over 1 years US$’000		Total US$’000
	(Unaudited)		(Unaudited)		(Unaudited)
Trade and notes payables		11,001		—		11,001
Other payables and accruals		24,756		—		24,756
Warrant liability		83,300		—		83,300
Interest-bearing loans and borrowings		—		17,310		17,310
Lease liabilities		1,178		1,629		2,807
		120,235		18,939		139,174

Capital management

The primary objectives of the Group’s capital management are to safeguard the Group’s ability to continue as a going concern and to maintain a strong credit rating and healthy capital ratios in order to support its business and maximise shareholders’ value.

The Group manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Group is not subject to any externally imposed capital requirements. No changes were made in the objectives, policies or processes for managing capital during the reporting periods.

The Group monitors capital using a gearing ratio, which is total liabilities divided by total assets. The gearing ratios as at the end of each period were as follows:

	December 31, 2020			June 30, 2021
	US$’000			US$’000
				(Unaudited)
Total liabilities		440,752			535,206
Total assets		721,007			875,125
Gearing ratio		61	%		61	%

Approval of the Interim Condensed Consolidated Financial Statements

6 Months Ended

Jun. 30, 2021

Statement Of Financial Position [Abstract]

Approval of the Interim Condensed Consolidated Financial Statements

23. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The interim condensed consolidated financial statements were approved and authorised for issue by the board of directors on August 23, 2021.

Operating Segment Information (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Operating Segments [Abstract]

Summary of Revenue from External Customers

(a) Revenue from external customers

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
North America		23,146		33,915

Summary of Non-current Assets

(b) Non-current assets

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
China		43,953		48,370
United States		78,022		98,455
Other countries		6,174		7,466
Total		128,149		154,291

Revenue, Other Income and Gains (Tables)

6 Months Ended

Jun. 30, 2021

Revenue Other Income And Gains [Abstract]

Summary of Analysis of Revenue

An analysis of revenue is as follows:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Revenue from contracts with customers
License and collaboration revenue
- Licensing of intellectual property		—		1,122
- JSC service		23,146		32,793
Total		23,146		33,915

Summary of Revenue Recognized That Included in Contract Liabilities at Beginning of Reporting Period and Performance Obligation Satisfied in Previous Periods

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Revenue recognized that was included in contract liabilities at the beginning of the reporting period:
License and collaboration revenue
- JSC service		23,146		27,408

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Revenue recognized from performance obligation satisfied in previous periods:
License and collaboration revenue
- Licensing of intellectual property		—		1,122
- JSC service		—		4,615
		—		5,737

Summary of Amounts of Transaction Prices Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied)

The amounts of transaction prices allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at December 31, 2020 and June 30, 2021 are as follows:

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Amounts expected to be recognized as revenue:
Within 1 year		55,014		56,139
1 - 2 years		55,014		56,139
2 - 3 years		55,014		56,139
3 - 4 years		55,014		56,139
After 4 years		110,029		84,211
		330,085		308,767

Other Income and Gains

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Other income and gains
Government grants*		1,945		1,323
Finance income		1,808		227
Fair value gains on financial assets at fair value change through profit or loss		39		—
Rental income		4		8
Others**		—		832
		3,796		2,390

*	The amount represents subsidies received from local government authorities to support the Group’s business. There were no unfulfilled conditions and other contingencies attached to these government grants.

**	The amount mainly represents reimbursement of depositary fees that are related to the establishment and maintenance of the ADR program.

Loss Before Tax (Tables)

6 Months Ended

Jun. 30, 2021

Profit Loss [Abstract]

Schedule of Profit Loss Before Tax Arrived After Charging and Crediting Explanatory

The Group’s loss before tax is arrived at after charging/(crediting):

			Six months ended June 30,
			2020			2021
	Notes		US$’000			US$’000
			(Unaudited)			(Unaudited)
Reversal for the impairment of trade receivables, net		9		(9	)		(22	)
IPO expenses				1,439			—
Employee benefit expense:
Wages and salaries				30,794			47,303
Pension scheme contributions (defined contribution schemes)				436			1,759
Equity-settled share-based compensation expense				668			8,033

Income Tax (Tables)

6 Months Ended

Jun. 30, 2021

Major Components Of Tax Expense Income [Abstract]

Summary of Tax Charges

	Six months ended June 30,
	2020			2021
	US$’000			US$’000
	(Unaudited)			(Unaudited)
Current – United States of America		(3,709	)		—
Current – Elsewhere		—			1
Total tax charge for the year		(3,709	)		1

Loss per Share Attributable to Ordinary Equity Holders of the Parent (Tables)

6 Months Ended

Jun. 30, 2021

Basic Earnings Per Share [Abstract]

Summary of Calculations of Basic and Diluted Loss per Share

The calculations of basic and diluted loss per share are based on:

	Six months ended June 30,
	2020			2021
	US$’000			US$’000
	(Unaudited)			(Unaudited)
Losses
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation		(179,104	)		(172,483	)

	Number of shares Six months ended June 30,
	2020		2021
	(Unaudited)		(Unaudited)
Shares
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation		207,775,944		271,684,977

Trade Receivables (Tables)

6 Months Ended

Jun. 30, 2021

Trade And Other Receivables [Abstract]

Summary of Trade Receivables

	December 31, 2020			June 30, 2021
	US$’000			US$’000
				(Unaudited)
Trade receivables		75,000			15,000
Less: Impairment of trade receivables		(22	)		—
		74,978			15,000

Summary of Movements in Loss Allowance for Impairment of Trade Receivables

Movements in the loss allowance for impairment of trade receivables were as follows:

	Total
	US$’000
At January 1, 2020		9
Impairment losses reversed		(9	)
Impairment losses recognised		22
At December 31, 2020		22
At January 1, 2021		22
Impairment losses reversed		(22	)
Impairment losses recognised		—
At June 30, 2021 (Unaudited)		—

Financial Investment Measured at Amortized Cost (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Financial Investment Measured At Amortized Cost [Abstract]

Summary of Financial Investment Measured at Amortized Cost

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)

Financial investment measured at amortized cost		—		29,849

Cash and Cash Equivalents and Pledged Deposits (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Cash And Cash Equivalents And Pledged Deposits [Abstract]

Summary of Cash and Cash Equivalents and Pledged Deposits

	December 31, 2020			June 30, 2021
	US$’000			US$’000
				(Unaudited)
Cash and bank balances		506,073			663,115
Less: pledged short-term deposits		(384	)		(256	)
time deposits		(50,000	)		(174,644	)
Cash and cash equivalents		455,689			488,215
Denominated in USD		451,165			472,722
Denominated in RMB		4,335			12,614
Denominated in EUR		189			2,879
Cash and cash equivalents		455,689			488,215

Trade and Notes Payables (Tables)

6 Months Ended

Jun. 30, 2021

Trade And Other Payables [Abstract]

Summary of Trade and Notes Payables

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Trade payables		4,911		11,001
Notes payables		327		—
		5,238		11,001

Warrant Liability (Tables)

6 Months Ended

Jun. 30, 2021

Warrant Liability [Abstract]

Summary of Movement of the ant Liability

The movement of the warrant liability is set out as below:

	Total
	US$’000
At January 1, 2021		—
Issuance of the warrant liability		81,700
Fair value loss of the warrant liability		1,600
At June 30, 2021		83,300

Interest-Bearing Loans and Borrowings (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Detailed Information About Borrowings [Abstract]

Summary of Interest-Bearing Loans and Borrowings

Effective interest rate (%)

Maturity

June 30,

2021

US$’000

(Unaudited)

Non-current

Loans from a collaborator

2.74

No specific maturity date

17,310

Share Capital and Share Premium (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Classes Of Share Capital [Abstract]

Summary of Shares

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Authorised:
500,000,000 ordinary shares of US$0.0001 each		50		50
Issued and fully paid:
266,010,256 and 289,428,096 ordinary shares of US$0.0001 each		27		29

Summary of Movements in the Company’s Share Capital and Share Premium

A summary of movements in the Company’s share capital and share premium is as follows:

	Number of shares in issue		Share capital		Share premium		Total
			US$’000		US$’000		US$’000
At December 31, 2019 and January 1, 2020		200,000,000		20		3,908		3,928
Issuance of ordinary shares for initial public offering, net of issuance costs		42,377,500		4		450,081		450,085
Issuance of ordinary shares for conversion of preferred shares		20,907,282		2		240,432		240,434
Issuance of ordinary shares for private placement by Genscript		1,043,478		—		12,000		12,000
Exercise of share option		1,681,996		1		1,885		1,886
At December 31, 2020		266,010,256		27		708,306		708,333


	Number of shares in issue		Share capital		Share premium		Total
			US$’000		US$’000		US$’000
At December 31, 2020 and January 1, 2021		266,010,256		27		708,306		708,333
Issuance of ordinary shares for an institutional investor		20,809,850		2		218,298		218,300
Exercise of share option		2,590,596		—		3,280		3,280
Vesting of RSU		17,394		—		200		200
At June 30, 2021 (Unaudited)		289,428,096		29		930,084		930,113

Notes to the Consolidated Statement of Cash Flows (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]

Summary of Changes in Liabilities Arising from Financing Activities

Changes in liabilities arising from financing activities

	Convertible redeemable preferred shares			Other payable to related parties			Lease liabilities
	US$’000			US$’000			US$’000
At January 1, 2020		—			4			6,085
Decrease of lease liabilities		—			—			(924	)
Changes from financing cash flows		160,450			(4	)		(1,723	)
Fair value loss of the Series A Preferred Shares		79,984			—			—
Conversion to ordinary shares		(240,434	)		—			—
Interest expense		—			—			105
Interest paid classified as operating cash flows		—			—			(105	)
Foreign exchange movement		—			—			(5	)
At June 30, 2020 (Unaudited)		—			—			3,433
At January 1, 2021		—			—			3,373
Changes from financing cash flows		—			—			(550	)
Interest expense		—			—			73
Interest paid classified as operating cash flows		—			—			(73	)
Foreign exchange movement		—			—			(24	)
At June 30, 2021 (Unaudited)		—			—			2,799

Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows

The total cash outflow for leases included in the statement of cash flows is as follows:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Right-of-use assets
Within operating activities		105		73
Within financing activities		1,723		550
Short-term leases		43		105
		1,871		728

Capital Commitments (Tables)

6 Months Ended

Jun. 30, 2021

Capital Commitments [Abstract]

Summary of Capital Commitments

The Group had the following capital commitments as at June 30, 2021:

Less than

one year

(Unaudited)

Construction in progress

23,954

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Transactions Between Related Parties [Abstract]

Summary of Nature of Related Party Relationship

Company		Relationship
Nanjing GenScript Biotech Co., Ltd.		Company controlled by the ultimate holding company
Jiangsu Genscript Biotech Co., Ltd.		Company controlled by the ultimate holding company
Genscript (HongKong) Ltd.		Company controlled by the ultimate holding company
Genscript USA Incorporated		Company controlled by the ultimate holding company
Genscript USA Holdings Inc		Company controlled by the ultimate holding company
CUSTOMARRAY, INC.		Company controlled by the ultimate holding company

Summary of Transactions with Related Parties

(a)

In addition to the transactions detailed elsewhere in these interim condensed consolidated financial statements, the Group had the following transactions with related parties during the period:

(i)

Purchases from related parties:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Nanjing GenScript Biotech Co., Ltd.		1,664		5,858
Genscript USA Incorporated		458		298
Jiangsu Genscript Biotech Co., Ltd.		13		124
		2,135		6,280

The transactions were made according to the terms and conditions agreed with related parties.

(ii)

Management fee:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Genscript USA Incorporated		95		21
Nanjing GenScript Biotech Co., Ltd.		—		95
		95		116

The management fee was charged by related parties based on the cost of services provided.

(iii)

Shared services:

(iv)

Repayment of cash advances from related parties:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Genscript (HongKong) Ltd.		4		—

The above cash advances from related parties were unsecured, interest free and repayable on demand.

(v)

Purchase of equipment

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Nanjing GenScript Biotech Co., Ltd.		52		—

The purchase of equipment was made at their respective carrying value.

(vi)

Compensation fee for termination of service agreement:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Jiangsu Genscript Biotech Co., Ltd.		—		2,649

Summary of Outstanding Balances with Related Parties

(b)

Outstanding balances with related parties:

The Group had the following significant balances with its related parties:

(i)

Due from related parties

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Other Receivables
Genscript USA Incorporated		6		12
Nanjing GenScript Biotech Co., Ltd.		14		32
Jiangsu Genscript Biotech Co., Ltd.		—		1
CUSTOMARRAY, INC.		—		1
		20		46

(ii)

Due to related parties

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Trade Payables
Nanjing GenScript Biotech Co., Ltd.		1,547		5,541
Genscript USA Incorporated		555		483
Jiangsu Genscript Biotech Co., Ltd.		1		124
		2,103		6,148

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Other Payables
Nanjing GenScript Biotech Co., Ltd.		3,736		2,137
Genscript USA Incorporated		—		12
Jiangsu Genscript Biotech Co., Ltd.		—		3,803
		3,736		5,952

	December 31, 2020		June 30, 2021
	US$’000		US$’000
			(Unaudited)
Lease Liabilities
Genscript USA Holdings Inc		582	297
Nanjing GenScript Biotech Co., Ltd.		351	391
		933	688

Summary of Compensation of Key Management Personnel

(c)

Compensation of key management personnel of the Group:

	Six months ended June 30,
	2020		2021
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Short-term employee benefits		913		1,007
Equity-settled share-based compensation expense		306		1,125
		1,219		2,132

Financial Instruments by Category (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Financial Instruments [Abstract]

Summary of Financial Assets

Financial assets

	Financial assets at amortised cost
	US$’000
Trade receivables		74,978
Financial assets included in prepayments, other receivables and other assets		344
Time deposits		50,000
Pledged deposits		384
Cash and cash equivalents		455,689
		581,395

Financial assets

	Financial assets at amortised cost
	US$’000
	(Unaudited)
Trade receivables		15,000
Financial assets included in prepayments, other receivables and other assets		487
Financial investment measured at amortized cost		29,849
Time deposits		174,644
Pledged deposits		256
Cash and cash equivalents		488,215
		708,451

Summary of Financial Liabilities

Financial liabilities

	Financial liabilities at amortised cost
	US$’000
Trade and notes payables		5,238
Financial liabilities included in other payables and accruals		85,559
Lease liabilities		3,373
		94,170

Financial liabilities

	Financial liabilities at fair value through profit and loss		Financial liabilities at amortised cost
	US$’000		US$’000
	(Unaudited)		(Unaudited)
Trade and notes payables		—		11,001
Warrant liability		83,300		—
Financial liabilities included in other payables and accruals		—		24,756
Interest-bearing loans and borrowings		—		17,310
Lease liabilities		—		2,799
		83,300		55,866

Fair Value and Fair Value Hierarchy of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Fair Value Of Financial Instruments [Abstract]

Summary of Fair Value Measurement Hierarchy of Financial Instruments

The following table illustrates the fair value measurement hierarchy of the Group’s financial instruments:

As at June 30, 2021 (Unaudited)
	Fair value measurement using
	Quoted prices in active markets (Level 1)		Significant observable inputs (Level 2)		Significant unobservable inputs (Level 3)		Total
	US$’000		US$’000		US$’000		US$’000
Warrant liability:		—		83,300		—		83,300
		—		83,300		—		83,300

Summary of Fair Value Valuation of Warrant Liability

The following table lists the inputs to the binominal model used for the fair value valuation of warrant liability:

	June 30, 2021
	(Unaudited)
Underlying stock price		US$20.53
Volatility		75.6%
Risk free rate		0.25%
Dividend		0%

Financial Risk Management Objectives and Policies (Tables)

6 Months Ended

Jun. 30, 2021

Disclosure Of Financial Instruments [Abstract]

Summary of Sensitivity to Reasonably Possible Change in Exchange Rates

	Increase/ (decrease) in the rate of foreign currency	Decrease/ (increase) in loss before tax
	%	US$’000
		(Unaudited)
Six months ended June 30, 2021
If US$ strengthens against RMB	5		1,011
If US$ weakens against RMB	-5		(1,011	)
If US$ strengthens against EUR	5		(680	)
If US$ weakens against EUR	-5		680

Six months ended June 30, 2020
If US$ strengthens against RMB	5		473
If US$ weakens against RMB	-5		(473	)
If US$ strengthens against EUR	5		(501	)
If US$ weakens against EUR	-5		501

Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments

The maturity profile of the Group’s financial liabilities as at the end of the reporting period, based on contractual undiscounted payments, is as follows:

As at December 31, 2020

	Less than 1 years US$’000		Over 1 years US$’000		Total US$’000
Trade payables		5,238		—		5,238
Other payables and accruals		85,559		—		85,559
Lease liabilities		1,464		2,099		3,563
		92,261		2,099		94,360

As at June 30, 2021

	Less than 1 years US$’000		Over 1 years US$’000		Total US$’000
	(Unaudited)		(Unaudited)		(Unaudited)
Trade and notes payables		11,001		—		11,001
Other payables and accruals		24,756		—		24,756
Warrant liability		83,300		—		83,300
Interest-bearing loans and borrowings		—		17,310		17,310
Lease liabilities		1,178		1,629		2,807
		120,235		18,939		139,174

Summary of Monitoring Capital Using Gearing Ratio

The Group monitors capital using a gearing ratio, which is total liabilities divided by total assets. The gearing ratios as at the end of each period were as follows:

	December 31, 2020			June 30, 2021
	US$’000			US$’000
				(Unaudited)
Total liabilities		440,752			535,206
Total assets		721,007			875,125
Gearing ratio		61	%		61	%

Corporate Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021
Disclosure Of Significant Investments In Subsidiaries [Abstract]
Address of entity's registered office	PO Box 10240, Harbour Place, 103 South Church Street, George Town, Grant Cayman KY1-1002, Cayman Islands
Country of incorporation	Cayman Islands
Date of incorporation	May 27, 2015

Operating Segment Information - Summary of Revenue from External Customers (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
North America
Disclosure Of Operating Segments [Line Items]
Revenue	$ 33,915,000	$ 23,146,000

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_32&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_34&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_103&doctype=Standard
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_102&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2020-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2020-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

+ Details

Operating Segment Information - Summary of Non-current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Operating Segments [Line Items]
Non-current assets	$ 154,291	$ 128,149
China
Disclosure Of Operating Segments [Line Items]
Non-current assets	48,370	43,953
United States
Disclosure Of Operating Segments [Line Items]
Non-current assets	98,455	78,022
Other Countries
Disclosure Of Operating Segments [Line Items]
Non-current assets	$ 7,466	$ 6,174

Operating Segment Information - Additional Information (Details) - North America - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Operating Segments [Line Items]
Revenue	$ 33,915,000	$ 23,146,000
Customer information	single customer	single customer

- Definition

+ References

+ Details

Revenue, Other Income and Gains - Summary of Analysis of Revenue (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Revenue from contracts with customers
Revenue from contracts with customers	$ 33,915	$ 23,146
Licensing of intellectual property
Revenue from contracts with customers
License and collaboration revenue	1,122
JSC service
Revenue from contracts with customers
License and collaboration revenue	$ 32,793	$ 23,146

Revenue, Other Income and Gains - Summary of Revenue Recognized That Was Included in Contract Liabilities at Beginning of Reporting Period (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
JSC service
License and collaboration revenue
Revenue recognized that was included in contract liabilities at the beginning of the reporting period	$ 27,408	$ 23,146

Revenue, Other Income and Gains - Summary of Revenue Recognized From Performance Obligation Satisfied in Previous Periods (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
License and collaboration revenue
Revenue recognized from performance obligation satisfied in previous periods	$ 5,737
Licensing of intellectual property
License and collaboration revenue
Revenue recognized from performance obligation satisfied in previous periods	1,122
JSC service
License and collaboration revenue
Revenue recognized from performance obligation satisfied in previous periods	$ 4,615

Revenue, Other Income and Gains - Summary of Amounts of Transaction Prices Allocated to Remaining Performance Obligations (Unsatisfied or Partially Unsatisfied) (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Amounts expected to be recognized as revenue	$ 308,767	$ 330,085
Within 1 year
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Amounts expected to be recognized as revenue	56,139	55,014
1 - 2 years
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Amounts expected to be recognized as revenue	56,139	55,014
2 - 3 years
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Amounts expected to be recognized as revenue	56,139	55,014
3 - 4 years
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Amounts expected to be recognized as revenue	56,139	55,014
After 4 years
Disclosure Of Transaction Price Allocated To Remaining Performance Obligations [Line Items]
Amounts expected to be recognized as revenue	$ 84,211	$ 110,029

Revenue, Other Income and Gains - Additional Information (Details) - JSC service	6 Months Ended
	Jun. 30, 2021
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Description of performance obligations expected to recognize	The amounts of transaction prices allocated to the remaining performance obligations which are expected to be recognised as revenue after one year
Performance obligations estimated collaboration period	9 years

Revenue, Other Income and Gains - Other Income and Gains (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Other income and gains
Government grants	$ 1,323	$ 1,945
Finance income	227	1,808
Fair value gains on financial assets at fair value change through profit or loss		39
Rental income	8	4
Others	832
Other income and gains	$ 2,390	$ 3,796

Loss Before Tax - Summery of loss before tax is arrived at after charging/(crediting) (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Profit Loss Before Tax [Line Items]
Reversal for the impairment of trade receivables, net	$ (22)	$ (9)
Employee benefit expense:
Equity-settled share-based compensation expense	8,033	668
Profit Loss Before Tax Arrived After Charging And Crediting
Profit Loss Before Tax [Line Items]
Reversal for the impairment of trade receivables, net	(22)	(9)
IPO expenses		1,439
Employee benefit expense:
Wages and salaries	47,303	30,794
Pension scheme contributions (defined contribution schemes)	1,759	436
Equity-settled share-based compensation expense	$ 8,033	$ 668

Income Tax - Additional Information (Details)	6 Months Ended
Income Tax - Additional Information (Details)	Jun. 30, 2021 EUR (€)
Hong Kong
Major Components Of Tax Expense Income [Line Items]
Income tax rate	16.50%
United States of America
Major Components Of Tax Expense Income [Line Items]
Income tax rate	21.00%
Withholding tax rate	30.00%
New Jersey
Major Components Of Tax Expense Income [Line Items]
Income tax rate	11.50%
Ireland
Major Components Of Tax Expense Income [Line Items]
Income tax rate	12.50%
Withholding tax rate	25.00%
Non-trading tax rate	25.00%
China
Major Components Of Tax Expense Income [Line Items]
Income tax rate	25.00%
Withholding tax rate	10.00%
Netherlands
Major Components Of Tax Expense Income [Line Items]
Income tax rate	25.00%
Withholding tax rate	15.00%
Income tax rate	16.50%
Taxable income	€ 200,000

Income Tax - Summary of Tax Charges (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Major Components Of Tax Expense Income [Line Items]
Total tax charge for the year	$ 1	$ (3,709)
United States
Major Components Of Tax Expense Income [Line Items]
Total tax charge for the year		$ (3,709)
Other Than U S
Major Components Of Tax Expense Income [Line Items]
Total tax charge for the year	$ 1

Loss per Share Attributable to Ordinary Equity Holders of the Parent - Additional Information (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Basic Earnings Per Share [Abstract]
Weighted average number of ordinary shares issued	271,684,977	207,775,944

Loss per Share Attributable to Ordinary Equity Holders of the Parent - Summary of Calculations of Basic and Diluted Loss per Share (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Basic Earnings Per Share [Abstract]
Loss attributable to ordinary equity holders of the parent, used in the basic earnings per share calculation	$ (172,483)	$ (179,104)
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation	271,684,977	207,775,944

Property, Plant and Equipment - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Property Plant And Equipment [Line Items]
Property plant and equipment acquired	$ 28,822,000	$ 25,250,000
License and Collaboration Agreement
Disclosure Of Property Plant And Equipment [Line Items]
Property plant and equipment acquired	$ 4,204,000	$ 7,294,000

Trade Receivables - Summary of Trade Receivables (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Financial Assets [Line Items]
Trade receivables	$ 15,000	$ 74,978
Less: Impairment of trade receivables		(22)	$ (9)
Gross Carrying Amount
Disclosure Of Financial Assets [Line Items]
Trade receivables	$ 15,000	$ 75,000

Trade Receivables - Additional Information (Details)	6 Months Ended
Trade Receivables - Additional Information (Details)	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Financial Assets [Line Items]
Percentage of concentration of credit risk of trade receivables due from one single customer under a license and collaboration agreement	100.00%	100.00%
Bottom of Range
Disclosure Of Financial Assets [Line Items]
Credit period of trade receivables	30 days
Top of Range
Disclosure Of Financial Assets [Line Items]
Credit period of trade receivables	90 days

Trade Receivables - Summary of Movements in Loss Allowance for Impairment of Trade Receivables (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Trade And Other Receivables [Abstract]
Beginning balance	$ 22	$ 9
Impairment losses reversed	$ (22)	(9)
Impairment losses recognised		22
Ending balance		$ 22

Financial Investment Measured at Amortized Cost - Summary of Financial Investment Measured at Amortized Cost (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Disclosure Of Financial Investment Measured At Amortized Cost [Abstract]
Financial investment measured at amortized cost	$ 29,849

Financial Investment Measured at Amortized Cost - Additional Information (Details)	6 Months Ended
	Jun. 30, 2021 USD ($)
Disclosure Of Financial Investment Measured At Amortized Cost [Line Items]
Financial investment principal amount	$ 29,849,000
Commercial Paper
Disclosure Of Financial Investment Measured At Amortized Cost [Line Items]
Financial investment principal amount	$ 30,000,000
Discounted bid yield percentage per annum	0.50%
Financial investment maturity period	1 year
Financial investment maturity date	Jun. 01, 2022

Cash and Cash Equivalents and Pledged Deposits - Summary of Cash and Cash Equivalents and Pledged Deposits (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020	Dec. 31, 2019
Disclosure of Cash and Cash Equivalents and Pledged Deposits [Line Items]
Cash and bank balances	$ 663,115,000	$ 506,073,000
Less: pledged short-term deposits	(256,000)	(384,000)
time deposits	(174,644,000)	(50,000,000)
Cash and cash equivalents	488,215,000	455,689,000	$ 562,391,000	$ 83,364,000
Denominated in USD
Disclosure of Cash and Cash Equivalents and Pledged Deposits [Line Items]
Cash and cash equivalents	472,722,000	451,165,000
Denominated in RMB
Disclosure of Cash and Cash Equivalents and Pledged Deposits [Line Items]
Cash and bank balances	12,614,000	4,335,000
Cash and cash equivalents	12,614,000	4,335,000
Denominated in EUR
Disclosure of Cash and Cash Equivalents and Pledged Deposits [Line Items]
Cash and cash equivalents	$ 2,879,000	$ 189,000

Cash and Cash Equivalents and Pledged Deposits - Additional Information (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Cash and Cash Equivalents and Pledged Deposits [Line Items]
Cash and bank balances	$ 663,115,000	$ 506,073,000
Denominated in RMB
Disclosure of Cash and Cash Equivalents and Pledged Deposits [Line Items]
Cash and bank balances	$ 12,614,000	$ 4,335,000

Trade and Notes Payables - Summary of Trade and Notes Payables (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Trade And Other Payables [Abstract]
Trade payables	$ 11,001	$ 4,911
Notes payables		327
Trade and notes payables	$ 11,001	$ 5,238

Trade and Notes Payables - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Trade And Notes Payables [Line Items]
Trade payables, term	60 days
Trade payables	$ 11,001,000	$ 4,911,000
Related Parties
Trade And Notes Payables [Line Items]
Trade payables	$ 6,148,000	$ 2,103,000

Convertible Redeemable Preferred Shares - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Issuance of ordinary shares	$ 218,300,000
Series A Preference Shares
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares issued	20,591,629
Price per share	$ 7.792
Issuance of ordinary shares	$ 160,450,000
Percentage of dividends	8.00%
Automatic conversion, description	Each Series A Preference Share will be automatically converted upon the closing of a Qualified IPO into a number of ordinary shares as is determined by dividing the Series A original issue price by a conversion price is equal to the lower of (i) the conversion price at the time in effect for such Series A Preference Share and (ii) the price per share that equals 90% of the lowest net price per ordinary share received by the Company in the Qualified IPO.
Redemption rights, description	At any time on or after the occurrence of a Trigger Event (as defined below), each investor may require the Company to redeem the Series A Preference Shares issued to the investor and require the Company to immediately pay the investor an amount equal to the redemption price, plus 8% annualized.
Fair value loss		$ 80,000,000

Warrant Liability - Additional Information (Details) - USD ($)		6 Months Ended
	May 13, 2021	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Warrant Liability [Line Items]
Total proceeds			$ 450,085,000
Fair value of warrant liability		$ 81,700,000
Warrant liability assessed		83,300,000
Fair value loss of warrant liability		$ 1,600,000
Ordinary Shares
Warrant Liability [Line Items]
Price per share		$ 0.0001		$ 0.0001
Warrant Liability
Warrant Liability [Line Items]
Fair value of warrant liability	$ 81,700,000
Warrant liability assessed		$ 83,300,000
Fair value loss of warrant liability		$ 1,600,000
Warrant Liability \| PIPE Offering \| Ordinary Shares
Warrant Liability [Line Items]
Number of shares issued	20,809,850
Price per share	$ 0.0001
Purchase price per ordinary share	$ 14.41625
Total proceeds	$ 300,000,000
Warrant exercisable exercise price per share	$ 20.00
Warrant Liability \| PIPE Offering \| Ordinary Shares \| Top of Range
Warrant Liability [Line Items]
Warrant exercisable	10,000,000

Warrant Liability - Summary of Movement of the Warrant Liability (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021 USD ($)
Warrant Liability [Abstract]
Issuance of the warrant liability	$ 81,700
Fair value loss of the warrant liability	1,600
At June 30, 2021	$ 83,300

Interest-Bearing Loans and Borrowings - Summary of Interest-Bearing Loans and Borrowings (Details) - Collaborator - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 18, 2021
Disclosure Of Detailed Information About Borrowings [Line Items]
Effective interest rate (%)	2.74%
Maturity	No specific maturity date
Borrowings	$ 17,310	$ 17,310

Interest-Bearing Loans and Borrowings - Additional Information (Details) - Collaborator - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 18, 2021
Disclosure Of Detailed Information About Borrowings [Line Items]
Funding advance	$ 17,310	$ 17,310
Borrowings, interest rate basis	The interest rate is based on the average annual London Interbank Offered Rate (LIBOR) for U.S. Dollars as reported in the Wall Street Journal on a quarterly basis on the due date, plus 250 basis points, calculated on the number of days from the date on which the Company applied such borrowings.

Share Capital and Share Premium - Summary of Shares (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Issued and fully paid:
266,010,256 and 289,428,096 ordinary shares of US$0.0001 each	$ 29,000	$ 27,000
Ordinary Shares
Authorised:
500,000,000 ordinary shares of US$0.0001 each	50,000	50,000
Issued and fully paid:
266,010,256 and 289,428,096 ordinary shares of US$0.0001 each	$ 29,000	$ 27,000

Share Capital and Share Premium - Summary of Shares (Parenthetical) (Details) - Ordinary Shares - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Number of shares authorized	500,000,000	500,000,000
Number of shares issued and fully paid	289,428,096	266,010,256
Price per share	$ 0.0001	$ 0.0001

Share Capital and Share Premium - Summary of Movements in the Company's Share Capital and Share Premium (Details) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	$ 708,333	$ 3,928	$ 3,928
Issuance of ordinary shares for initial public offering, net of issuance costs		450,085	450,085
Issuance of ordinary shares for conversion of preferred shares			240,434
Issuance of ordinary shares relating to private placement for Genscript		12,000	12,000
Issuance of ordinary shares for an institutional investor	218,300
Exercise of share option	3,280		1,886
Vesting of RSU	200
Ending balance	930,113		708,333
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	27	20	20
Issuance of ordinary shares for initial public offering, net of issuance costs			4
Issuance of ordinary shares for conversion of preferred shares			2
Issuance of ordinary shares for an institutional investor	2
Exercise of share option			1
Ending balance	29		27
Share Premium
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	708,306	3,908	3,908
Issuance of ordinary shares for initial public offering, net of issuance costs		450,081	450,081
Issuance of ordinary shares for conversion of preferred shares			240,432
Issuance of ordinary shares relating to private placement for Genscript		$ 12,000	12,000
Issuance of ordinary shares for an institutional investor	218,298
Exercise of share option	3,280		1,885
Vesting of RSU	200
Ending balance	$ 930,084		$ 708,306
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Beginning balance	266,010,256	200,000,000	200,000,000
Issuance of ordinary shares for initial public offering, net of issuance costs			42,377,500
Issuance of ordinary shares for conversion of preferred shares			20,907,282
Issuance of ordinary shares for private placement by Genscript			1,043,478
Issuance of ordinary shares for an institutional investor	20,809,850
Exercise of share option	2,590,596		1,681,996
Vesting of RSU	17,394
Ending balance	289,428,096		266,010,256
Issuance of ordinary shares for initial public offering, net of issuance costs		$ 4

Notes to the Consolidated Statement of Cash Flows - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Notes To Consolidated Statement Of Cash Flows [Abstract]
Non-cash deductions to right of use assets		$ 924,000
Non-cash deductions in lease liabilities		924,000
Non-cash additions to finance costs		3,764,000
Non-cash other payable		3,764,000
Non-cash financing proceeds from the issuance of ordinary shares relating to a private placement for Genscript		$ 12,000,000
Non-cash additions to interest-bearing loans and borrowings	$ 17,310,000

Notes to the Consolidated Statement of Cash Flows - Summary of Changes in Liabilities Arising from Financing Activities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Convertible Redeemable Preferred Shares
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Changes from financing cash flows		$ 160,450
Fair value loss of the Series A Preferred Shares		79,984
Conversion to ordinary shares		(240,434)
Other Payables to Related Parties
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance		4
Changes from financing cash flows		(4)
Lease Liabilities
Disclosure Of Reconciliation Of Liabilities Arising From Financing Activities [Line Items]
Beginning balance	$ 3,373	6,085
Decrease of lease liabilities		(924)
Changes from financing cash flows	(550)	(1,723)
Interest expense	73	105
Interest paid classified as operating cash flows	(73)	(105)
Foreign exchange movement	(24)	(5)
Ending balance	$ 2,799	$ 3,433

Notes to the Consolidated Statement of Cash Flows - Summary of Total Cash Outflow for Leases Included in Statement of Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Right-of-use assets
Within operating activities	$ 73	$ 105
Within financing activities	550	1,723
Short-term leases	105	43
Cash outflow for leases	$ 728	$ 1,871

Capital Commitments - Summary of Capital Commitments (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Capital Commitments [Abstract]
Construction in progress	$ 23,954

Related Party Transactions - Summary of Nature of Related Party Relationship (Details)	6 Months Ended
	Jun. 30, 2021
Nanjing GenScript Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Jiangsu Genscript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript (HongKong) Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript USA Incorporated
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
Genscript USA Holdings Inc
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company
CUSTOMARRAY, INC.
Disclosure Of Transactions Between Related Parties [Line Items]
Relationship	Company controlled by the ultimate holding company

Related Party Transactions - Summary of Transactions with Related Parties (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	$ 6,280	$ 2,135
Management fee	116	95
Repayment of cash advances from related parties		4
Nanjing GenScript Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	5,858	1,664
Management fee	95
Purchase of equipment		52
Genscript USA Incorporated
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	298	458
Management fee	21	95
Jiangsu Genscript Biotech Co., Ltd
Disclosure Of Transactions Between Related Parties [Line Items]
Purchases from related parties	124	13
Compensation fee for termination of service agreement	$ 2,649
Genscript (HongKong) Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Repayment of cash advances from related parties		$ 4

Related Party Transactions - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Bottom of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Lessee's incremental borrowing rate applied to lease liabilities	2.00%
Lease liabilities, repayment term	5 years
Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Lessee's incremental borrowing rate applied to lease liabilities	7.28%
Nanjing GenScript Biotech Co., Ltd.
Disclosure Of Transactions Between Related Parties [Line Items]
Consideration paid for shared services	$ 1,040,000	$ 1,998,000

Related Party Transactions - Summary of Outstanding Balances with Related Parties (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Lease Liabilities
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	$ 688	$ 933
Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Due from related parties	46	20
Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	6,148	2,103
Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	5,952	3,736
Genscript USA Incorporated \| Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Due from related parties	12	6
Genscript USA Incorporated \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	483	555
Genscript USA Incorporated \| Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	12
Nanjing GenScript Biotech Co., Ltd. \| Lease Liabilities
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	391	351
Nanjing GenScript Biotech Co., Ltd. \| Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Due from related parties	32	14
Nanjing GenScript Biotech Co., Ltd. \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	5,541	1,547
Nanjing GenScript Biotech Co., Ltd. \| Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	2,137	3,736
Jiangsu Genscript Biotech Co., Ltd \| Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Due from related parties	1
Jiangsu Genscript Biotech Co., Ltd \| Trade Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	124	1
Jiangsu Genscript Biotech Co., Ltd \| Other Payables
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	3,803
CUSTOMARRAY, INC. \| Other Receivables
Disclosure Of Transactions Between Related Parties [Line Items]
Due from related parties	1
Genscript USA Holdings Inc \| Lease Liabilities
Disclosure Of Transactions Between Related Parties [Line Items]
Due to related parties	$ 297	$ 582

Related Party Transactions - Summary of Compensation of Key Management Personnel (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Transactions Between Related Parties [Abstract]
Short-term employee benefits	$ 1,007	$ 913
Equity-settled share-based compensation expense	1,125	306
Key management personnel compensation	$ 2,132	$ 1,219

Financial Instruments by Category - Summary of Financial Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	$ 708,451	$ 581,395
Trade Receivables
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	15,000	74,978
Financial Assets Included in Prepayments, Other Receivables and Other Assets
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	487	344
Financial Investment Measured at Amortized Cost
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	29,849
Time Deposits
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	174,644	50,000
Pledged Deposits
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	256	384
Cash and Cash Equivalents
Disclosure Of Financial Assets [Line Items]
Financial assets at amortised cost	$ 488,215	$ 455,689

Financial Instruments by Category - Summary of Financial Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortised cost	$ 55,866	$ 94,170
Financial liabilities at fair value through profit and loss	83,300
Trade and Notes Payables
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortised cost	11,001	5,238
Financial Liabilities Included in Other Payables and Accruals
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortised cost	24,756	85,559
Lease Liabilities
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortised cost	2,799	$ 3,373
Warrant Liability
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at fair value through profit and loss	83,300
Interest-bearing Loans and Borrowings
Disclosure Of Financial Liabilities [Line Items]
Financial liabilities at amortised cost	$ 17,310

Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Measurement Hierarchy of Financial Instruments (Details) $ in Thousands	Jun. 30, 2021 USD ($)
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]
Liability measured at fair value	$ 83,300
Warrant Liability
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]
Liability measured at fair value	83,300
Significant Observable Inputs (Level 2)
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]
Liability measured at fair value	83,300
Significant Observable Inputs (Level 2) \| Warrant Liability
Disclosure Fair Value Measurement Hierarchy Of Financial Instruments [Line Items]
Liability measured at fair value	$ 83,300

Fair Value and Fair Value Hierarchy of Financial Instruments - Summary of Fair Value Valuation of Warrant Liability (Details) - Warrant Liability	6 Months Ended
	Jun. 30, 2021 $ / shares
Disclosure Of Fair Value Valuation Of Warrant Liability [Line Items]
Underlying stock price	$ 20.53
Volatility	75.60%
Risk free rate	0.25%
Dividend	0.00%

Fair Value and Fair Value Hierarchy of Financial Instruments - Additional Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Abstract]
Fair value, assets, level 1 to level 2 transfers	$ 0	$ 0
Fair value, assets, level 2 to level 1 transfers	0	0
Fair value, liabilities, level 1 to level 2 transfers	0	0
Fair value, liabilities, level 2 to level 1 transfers	0	0
Fair value, measurement asset transfers into level 3	0	0
Fair value, measurement asset transfers out of level 3	0	0
Fair value, measurement liability, transfers into level 3	0	0
Fair value, measurement liability, transfers out of level 3	$ 0	$ 0

Financial Risk Management Objectives and Policies - Additional Information (Details) - Foreign Currency Risk - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]
Percentage of foreign currency forward exchange contract	36.00%	23.00%
Outstanding foreign currency forward exchange contracts	$ 0		$ 0

Financial Risk Management Objectives and Policies - Summary of Sensitivity to Reasonably Possible Change in Exchange Rates (Details) - Foreign Currency Risk - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
US$ Strengthens Against RMB
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	5.00%	5.00%
Decrease/ (increase) in loss before tax	$ 1,011	$ 473
US$ Weakens Against RMB
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	(5.00%)	(5.00%)
Decrease/ (increase) in loss before tax	$ (1,011)	$ (473)
US$ Strengthens Against EUR
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	5.00%	5.00%
Decrease/ (increase) in loss before tax	$ (680)	$ (501)
US$ Weakens Against EUR
Disclosure Of Financial Instruments [Line Items]
Increase/ (decrease) in the rate of foreign currency	(5.00%)	(5.00%)
Decrease/ (increase) in loss before tax	$ 680	$ 501

Financial Risk Management Objectives and Policies - Summary of Maturity Profile of Financial Liabilities Based on Contractual Undiscounted Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]
Trade payables	$ 11,001	$ 4,911
Other payables and accruals	109,183	99,168
Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Trade payables		5,238
Trade and notes payables	11,001
Other payables and accruals	24,756	85,559
Warrant liability	83,300
Interest-bearing loans and borrowings	17,310
Lease liabilities	2,807	3,563
Financial liabilities	139,174	94,360
Within 1 year \| Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Trade payables		5,238
Trade and notes payables	11,001
Other payables and accruals	24,756	85,559
Warrant liability	83,300
Lease liabilities	1,178	1,464
Financial liabilities	120,235	92,261
Over 1 years \| Liquidity Risk
Disclosure Of Financial Instruments [Line Items]
Interest-bearing loans and borrowings	17,310
Lease liabilities	1,629	2,099
Financial liabilities	$ 18,939	$ 2,099

Financial Risk Management Objectives and Policies - Summary of Monitoring Capital Using Gearing Ratio (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure Of Financial Instruments [Line Items]
Total liabilities	$ 535,206	$ 440,752
Total assets	875,125	721,007
Capital Management
Disclosure Of Financial Instruments [Line Items]
Total liabilities	535,206	440,752
Total assets	$ 875,125	$ 721,007
Gearing ratio	61.00%	61.00%